Review of NICE Technology Appraisal Guidance No. 214; Bevacizumab in combination with a taxane for the first line treatment of metastatic breast cancer

The Institute was proposing that TA214 should be transferred to the static list.

During consultation, only a small number of comments were received, and these were in agreement with the proposal.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

Consequently, TA214 will now be moved to the static list.  Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

September 2013